Rebiopsying for Prostate Cancer

April 28, 2014
E. David Crawford, MD

E. David Crawford, MD, professor, Urologic and Radiation Oncology, head, Section of Urologic Oncology, University of Colorado at Denver, discusses rebiopsying for prostate cancer.

E. David Crawford, MD, professor, Urologic and Radiation Oncology, head, Section of Urologic Oncology, University of Colorado at Denver, discusses rebiopsying for prostate cancer.

Clinical Pearls:

  • Each year in the U.S., 1.3-1.4 million biopsies are performed for prostate cancer, with only 240,000 leading to diagnoses
  • The need for a test to determine which men should be rebiopsied may have been answered by the ConfirmMDx test
  • Methylation tests look for DNA changes in normal tissue on a biopsy that potentially was around the cancer
  • If the test is negative and no genes are methylated, the physician is presented with a 90%-plus positive predictive value that the man does not have cancer. If the test is negative and the man does have cancer, it is typically low-grade and would not be treated anyway.